Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

. 2017 Sep 21 ; 377 (12) : 1119-1131. [epub] 20170827

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid28845751

Grantová podpora
K23 NS073806 NINDS NIH HHS - United States

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

Long-chain polyunsaturated fatty acid-containing phosphatidylcholines predict survival rate in patients after heart failure

. 2024 Nov 15 ; 10 (21) : e39979. [epub] 20241030

The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia

. 2024 Sep 23 ; 25 (18) : . [epub] 20240923

A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

. 2024 Feb ; 30 (2) : 424-434. [epub] 20240219

Microenvironmental regulation of T-cells in pulmonary hypertension

. 2023 ; 14 () : 1223122. [epub] 20230711

Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions

. 2022 ; 9 () : 1051995. [epub] 20221114

Rapid Drop in Coronary Heart Disease Mortality in Czech Male Population-What Was Actually behind It?

. 2022 Nov 09 ; 10 (11) : . [epub] 20221109

Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

. 2022 Mar 15 ; 23 (6) : . [epub] 20220315

Cholesterol in the Cell Membrane-An Emerging Player in Atherogenesis

. 2022 Jan 04 ; 23 (1) : . [epub] 20220104

Adipose tissue macrophages and atherogenesis - a synergy with cholesterolaemia

. 2021 Dec 30 ; 70 (Suppl4) : S535-S549.

Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial

. 2021 Jun ; 6 (2) : 222-228. [epub] 20210618

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

. 2020 Dec ; 22 (12) : 2272-2289. [epub] 20201112

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?

. 2020 ; 11 () : 619273. [epub] 20210126

Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'

. 2019 Dec ; 6 (6) : 1140-1148. [epub] 20191228

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

. 2019 Sep ; 17 (9) : e3000354. [epub] 20190916

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

. 2019 Jun 04 ; 18 (1) : 71. [epub] 20190604

Subsequent Event Risk in Individuals With Established Coronary Heart Disease

. 2019 Apr ; 12 (4) : e002470. [epub] 20190321

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01327846, NCT01327846

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...